Form D · Biotechnology
Everest Biolabs, Inc.
Waltham, MA · CIK 0002116676
Offering snapshot reported Mar 11, 2026 · SEC filing
- Reported sold
- $4.35M Offering amount: $5.65M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 25, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 11, 2026 | Initial | $4,350,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-576080
Source: Form D, filed Mar 11, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| George Daaboul | Director, Executive |
| David Freedman | Director, Executive |
| Paul Meister | Director |
| Vinit Nijhawan | Director |
| David Walt | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
204 Second Ave Suite 102
Waltham, MA, 02451
Waltham, MA, 02451